COLORADO SPRINGS, Colo.,
Oct. 14, 2013 /PRNewswire/ -- Endocan
Corporation (NASDAQ OTC: XCHC) a U.S. Company specializing in
cannabinoid formulation-based health and wellness solutions, is
pleased to announce that the name change and the updated and
revised Company website and corporate collateral package, will be
released Thursday, October 17,
2013.
Endocan Corporation is creating an enhanced international brand
and image with a blend of scientific expertise and patient
orientated products to attack critical ailments and help promote an
enhanced healthy autoimmune system to help maintain and regulate a
strong healthy mind and body state with its proprietary cannabis
based formulations and procedures.
Dr. Dorothy Bray, President &
CEO, Endocan Corporation, stated, "We are on the cusp of our new
product releases, designed for patients internationally. We will
offer patients educational support and the opportunity of voluntary
participation in our in-house tracking and anonymized data sharing
systems through our new website noting patient feedback to improve
future product development and new product release systems."
In the United States dispensary
owners across the United States
will be licensed to release the Company's brands and formulations
for retail distribution through licensing agreements utilizing the
Endocan™ brand name. In Canada the
Company has an established network of professionals and regulatory
experts to bring its products to market for patient use. Initially
the Company will be releasing its formulations through several
expert relationships across Canada. The Company has established two
subsidiaries in The Netherlands,
including Endocan B.V., for the Company's expanding European
operations.
About Endocan Corporation
The brand name Endocan™ was chosen by the Board as a direct
reference to the endocannabinoid system of the human body. The
endocannabinoid system is a group of neuromodulatory compounds and
their receptors that are involved in a variety of fundamental
physiological processes including pain-sensation, immune function,
stress, sleep, mood, appetite, and memory. Cannabinoids from
plants, including those found in the Cannabis genus, as well as
those autonomously produced within living biological systems, work
together in the operation of the endocannabinoid system. The
modulation of this system is the basis for cannabinoid-based
medical treatments to assist patients to improve their health and
well-being.
Endocan Corporation, (FKA The X-Change Corporation) is currently
developing new natural cannabinoid containing products based on
innovative formulations to utilize the unique and potent benefits
of the cannabis and hemp plants. Medicinal properties of cannabis
and hemp have been known and applied for thousands of years. With
the aid of scientific research, Endocan Corporation is translating
such knowledge into development of effective cannabinoid
formulation-based health and wellness solutions as well as
cosmeceutical, nutraceutical, and food brands throughout the world.
The Company's health and wellness, nutritional, and cosmetics lines
will address personal needs and will evolve with the introduction
of new formulations and products, advancing the Company within the
expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. The Company does not undertake any duty nor does it intend
to update the results of these forward-looking statements.
X-Change Corp.
President
Dr. Dorothy Bray
info@xchangecorp.com
www.xchangecorp.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
rkane@xchangecorp.com
+1.561.420.4824
SOURCE Endocan Corporation